Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
Acute single-dose response of drug-induced parkinsonism (DIP) to L-Dopa and apomorphine challenge was evaluated in a double-blind crossover study in 12 schizophrenic patients. There were two noteworthy negative findings. First, neither L-Dopa nor apomorphine produced significant improvements in DIP and second, no changes (neither improvement nor worsening) were found in patients' psychiatric status. Findings suggest that, for a stimulation dose reaching almost 90% of the responsive dose for idiopathic Parkinson's disease, no significant changes may reasonably be expected in the parkinsonism of schizophrenic patients treated with neuroleptic drugs.
Merello
M
M
Department of Clinical Neurology, Neuropsychiatric Hospital, Raul Carrea Institute for Neurological Research FLENI, Buenos Aires, Argentina.
Starkstein
S
S
Petracca
G
G
Cataneo
E A
EA
Manes
F
F
Leiguarda
R
R
D000328:Adult; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D001058:Apomorphine / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D007980:Levodopa; D001058:Apomorphine